Clinic
Inova Health Care Services
Inova Health Care Services was paid $176.68M by Medicaid between Jan 2018 and Dec 2024, across 636 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoINOVA HEALTH CARE SERVICES
FALLS CHURCH, VA 22042
FALLS CHURCH, VA 22042
33aNPI1831220714assigned 03/09/2007
33bProvider typeSubstance Use Disorder Rehabilitation Clinic/Center
28Total paid$176.68M
24GClaims2,860,436
24DCodes billed636
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Substance Use Disorder Rehabilitation Clinic/Center providers in Virginia
Rank by total paid#1 of 22
Median peer was paid$2.19M
This provider vs. median81×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 266,795 | $9.51M | |
| 2019 | 353,060 | $13.85M | |
| 2020 | 308,208 | $14.98M | |
| 2021 | 403,967 | $21.71M | |
| 2022 | 478,853 | $31.34M | |
| 2023 | 557,387 | $41.75M | |
| 2024incomplete | 492,166 | $43.54M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 165,979 | 146,936 | $33.52M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 93,180 | 81,522 | $20.09M |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.9% | 40,258 | 30,590 | $12.20M |
| G0378 | Hospital observation service, per hour | 5.1% | 29,404 | 24,666 | $8.98M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 4.9% | 62,975 | 50,384 | $8.64M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.9% | 31,597 | 28,321 | $6.96M |
| J9271 | Injection, pembrolizumab, 1 mg | 3.9% | 1,433 | 1,099 | $6.87M |
| 44970 | 3.5% | 1,311 | 1,273 | $6.19M | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.8% | 28,893 | 26,487 | $5.01M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 18,295 | 16,144 | $3.21M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.6% | 9,082 | 8,216 | $2.85M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.5% | 10,703 | 6,430 | $2.60M |
624 more codes
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.3% | 16,216 | $2.34M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 19,993 | $2.33M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.2% | 13,245 | $2.13M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.2% | 3,924 | $2.05M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 14,878 | $1.95M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 9,940 | $1.71M |
| 96415 | <1% | 4,378 | $1.69M | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 2,237 | $1.26M |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 13,794 | $1.21M |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 4,769 | $1.08M |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 17,168 | $974K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 2,767 | $893K |
| 76770 | <1% | 5,942 | $885K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 17,275 | $882K |
| 36430 | <1% | 3,420 | $879K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,540 | $872K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 17,380 | $853K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 10,820 | $837K |
| J1459 | Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | <1% | 811 | $824K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 6,520 | $808K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 928 | $804K |
| 47562 | <1% | 189 | $790K | |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | <1% | 3,542 | $735K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 4,919 | $732K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,183 | $727K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 7,573 | $692K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,453 | $656K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 6,854 | $647K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 756 | $615K |
| 58661 | <1% | 296 | $612K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 14,190 | $599K |
| J0485 | Injection, belatacept, 1 mg | <1% | 1,666 | $598K |
| 59025 | Fetal non-stress test | <1% | 3,493 | $588K |
| 96367 | <1% | 6,370 | $522K | |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | <1% | 213 | $515K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,160 | $508K |
| 80053 | Comprehensive metabolic panel | <1% | 115,005 | $505K |
| 93976 | <1% | 6,047 | $435K | |
| 96416 | <1% | 1,601 | $427K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 1,019 | $414K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 4,533 | $414K |
| 93458 | <1% | 264 | $409K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,700 | $408K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 5,340 | $408K |
| 12001 | <1% | 1,698 | $384K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 4,767 | $377K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 3,823 | $376K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 470 | $374K |
| 76830 | Ultrasound, transvaginal | <1% | 4,037 | $358K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 1,986 | $354K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 3,386 | $353K |
| 12011 | <1% | 1,580 | $353K | |
| 76536 | <1% | 2,310 | $286K | |
| J9202 | Goserelin acetate implant, per 3.6 mg | <1% | 381 | $280K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 35,228 | $277K |
| 76642 | <1% | 2,244 | $256K | |
| 64483 | <1% | 282 | $254K | |
| 97161 | <1% | 3,962 | $252K | |
| 93971 | <1% | 2,692 | $241K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 748 | $239K |
| 76801 | <1% | 5,556 | $238K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,296 | $238K |
| 92526 | <1% | 4,772 | $236K | |
| 96450 | <1% | 528 | $235K | |
| 97165 | <1% | 3,753 | $235K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 94 | $228K |
| 93798 | <1% | 2,436 | $218K | |
| 76870 | <1% | 2,207 | $216K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,257 | $216K |
| 64615 | <1% | 479 | $212K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 7,886 | $206K |
| 77336 | <1% | 2,235 | $205K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 5,580 | $200K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 17,770 | $196K |
| 93017 | <1% | 2,246 | $193K | |
| 92610 | <1% | 1,993 | $188K | |
| 93970 | <1% | 1,540 | $188K | |
| 97116 | <1% | 7,372 | $179K | |
| 97162 | <1% | 2,629 | $175K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 9,270 | $172K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 49,718 | $167K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 7,079 | $166K |
| 76885 | <1% | 1,130 | $160K | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 752 | $158K |
| 76820 | <1% | 3,579 | $156K | |
| 95782 | <1% | 191 | $154K | |
| 77523 | <1% | 151 | $153K | |
| 92523 | <1% | 769 | $148K | |
| 75574 | <1% | 452 | $146K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 38,892 | $144K |
| P9045 | Infusion, albumin (human), 5%, 250 ml | <1% | 699 | $144K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 19,416 | $142K |
| 71250 | <1% | 2,270 | $136K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 45,134 | $135K |
| 94618 | <1% | 1,589 | $130K | |
| 70496 | <1% | 624 | $127K | |
| 93325 | <1% | 1,547 | $124K | |
| 93656 | <1% | 15 | $122K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 9,320 | $120K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 2,343 | $120K |
| G0410 | Group psychotherapy other than of a multiple-family group, in a partial hospitalization or intensive outpatient setting, approximately 45 to 50 minutes | <1% | 758 | $118K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 64,915 | $116K |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 105 | $113K |
| 87400 | <1% | 10,739 | $106K | |
| 76821 | <1% | 2,788 | $105K | |
| 56820 | <1% | 563 | $103K | |
| 87040 | <1% | 15,741 | $102K | |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 60 | $102K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,801 | $98K |
| 70491 | <1% | 510 | $95K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,846 | $95K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,423 | $94K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 142,980 | $93K |
| 77300 | <1% | 668 | $90K | |
| 97166 | <1% | 1,462 | $89K | |
| 31624 | <1% | 164 | $88K | |
| 70498 | <1% | 937 | $88K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,116 | $86K |
| 29125 | <1% | 612 | $85K | |
| J3490 | Unclassified drugs | <1% | 62,208 | $81K |
| 86923 | <1% | 3,602 | $77K | |
| J9299 | Injection, nivolumab, 1 mg | <1% | 28 | $74K |
| J9306 | Injection, pertuzumab, 1 mg | <1% | 38 | $74K |
| 70544 | <1% | 377 | $74K | |
| 77334 | <1% | 624 | $73K | |
| 95886 | <1% | 552 | $72K | |
| 95885 | <1% | 509 | $72K | |
| 94010 | <1% | 2,730 | $71K | |
| 96402 | <1% | 2,443 | $70K | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 866 | $69K |
| 77412 | <1% | 93 | $69K | |
| 12002 | <1% | 340 | $67K | |
| 29105 | <1% | 650 | $67K | |
| 83880 | <1% | 8,742 | $65K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 145 | $64K |
| 74174 | <1% | 348 | $64K | |
| 70486 | <1% | 1,578 | $64K | |
| 74018 | <1% | 8,127 | $63K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 4,552 | $63K |
| 71045 | Radiologic examination, chest; single view | <1% | 21,907 | $63K |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | <1% | 267 | $62K |
| 58558 | <1% | 27 | $62K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 31,562 | $61K |
| 82247 | <1% | 8,246 | $59K | |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | <1% | 69 | $56K |
| 85027 | <1% | 22,692 | $55K | |
| 96409 | <1% | 2,789 | $54K | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 272 | $53K |
| 88307 | <1% | 3,528 | $53K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 4,004 | $52K |
| 77066 | Tomosynthesis, mammo | <1% | 1,024 | $52K |
| 72131 | <1% | 1,341 | $51K | |
| 93308 | <1% | 179 | $50K | |
| G0177 | Training and educational services related to the care and treatment of patient's disabling mental health problems per session (45 minutes or more) | <1% | 1,197 | $50K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 128 | $49K |
| 87505 | <1% | 1,013 | $49K | |
| 77386 | <1% | 123 | $49K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 16,115 | $49K |
| 96523 | <1% | 886 | $47K | |
| 86850 | <1% | 16,645 | $45K | |
| S0201 | Partial hospitalization services, less than 24 hours, per diem | <1% | 87 | $44K |
| 90715 | <1% | 2,058 | $43K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 4,312 | $43K |
| 77387 | <1% | 686 | $42K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,764 | $41K |
| 64447 | <1% | 110 | $41K | |
| 77080 | <1% | 555 | $40K | |
| 86780 | <1% | 4,173 | $39K | |
| 80143 | <1% | 9,746 | $38K | |
| 87420 | <1% | 2,739 | $36K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 16,093 | $36K |
| 84484 | <1% | 28,781 | $35K | |
| 95816 | <1% | 146 | $34K | |
| 74230 | <1% | 335 | $33K | |
| 72100 | <1% | 1,868 | $33K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 579 | $32K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 28,943 | $32K |
| 77065 | Tomosynthesis, mammo | <1% | 615 | $32K |
| 76942 | <1% | 518 | $31K | |
| 72040 | <1% | 1,056 | $31K | |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | <1% | 270 | $31K |
| 54161 | <1% | 14 | $31K | |
| 10060 | <1% | 245 | $31K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 82 | $30K |
| 87081 | <1% | 18,980 | $29K | |
| 76882 | <1% | 304 | $29K | |
| 88341 | <1% | 2,555 | $29K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 96 | $28K |
| 82248 | <1% | 18,470 | $28K | |
| 95700 | <1% | 168 | $27K | |
| 36591 | <1% | 2,884 | $27K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 189 | $26K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 18,103 | $26K |
| 85379 | <1% | 4,958 | $25K | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 1,266 | $25K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,488 | $24K |
| 86900 | <1% | 19,519 | $24K | |
| 73564 | <1% | 2,591 | $24K | |
| 73030 | <1% | 3,098 | $23K | |
| 83735 | <1% | 31,456 | $23K | |
| 76813 | <1% | 558 | $23K | |
| J9070 | Cyclophosphamide, 100 mg | <1% | 287 | $22K |
| 96401 | <1% | 617 | $22K | |
| 94729 | <1% | 815 | $22K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,271 | $21K |
| S0028 | Injection, famotidine, 20 mg | <1% | 18,665 | $19K |
| 80179 | <1% | 9,592 | $19K | |
| 77301 | <1% | 24 | $19K | |
| 74019 | <1% | 5,100 | $19K | |
| 73560 | <1% | 1,637 | $18K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 926 | $18K |
| 72110 | <1% | 767 | $18K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 10,226 | $18K |
| 25605 | <1% | 41 | $17K | |
| 94726 | <1% | 358 | $17K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 16,544 | $17K |
| 77295 | <1% | 26 | $17K | |
| 64493 | <1% | 13 | $16K | |
| 77470 | <1% | 39 | $16K | |
| 87497 | <1% | 1,843 | $16K | |
| 83605 | <1% | 12,650 | $16K | |
| 78306 | <1% | 53 | $16K | |
| 73610 | <1% | 4,211 | $16K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 2,092 | $15K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 198 | $15K |
| 95811 | <1% | 25 | $15K | |
| 43235 | <1% | 27 | $15K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 51,731 | $15K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,017 | $15K |
| 81001 | <1% | 42,324 | $15K | |
| 84702 | <1% | 12,170 | $15K | |
| 73130 | <1% | 2,381 | $15K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 50 | $15K |
| 85610 | <1% | 18,346 | $15K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,736 | $15K |
| 80197 | <1% | 3,262 | $15K | |
| 73630 | <1% | 3,772 | $14K | |
| 29515 | <1% | 235 | $14K | |
| 88185 | <1% | 442 | $14K | |
| 82105 | <1% | 1,475 | $14K | |
| 76825 | <1% | 111 | $14K | |
| 62323 | <1% | 14 | $13K | |
| 86803 | <1% | 2,714 | $13K | |
| 73700 | <1% | 180 | $13K | |
| 80061 | Lipid panel | <1% | 4,176 | $13K |
| 72070 | <1% | 714 | $13K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 2,663 | $13K |
| 95910 | <1% | 155 | $12K | |
| 80047 | <1% | 1,664 | $12K | |
| 92611 | <1% | 307 | $12K | |
| 86901 | <1% | 19,511 | $12K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 279 | $11K |
| 84439 | <1% | 5,079 | $11K | |
| 86830 | <1% | 667 | $11K | |
| 76776 | <1% | 226 | $11K | |
| 73502 | <1% | 1,149 | $11K | |
| 82728 | <1% | 4,243 | $10K | |
| 82533 | <1% | 1,482 | $10K | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 34,320 | $10K |
| 96376 | <1% | 17,571 | $10K | |
| 95911 | <1% | 140 | $10K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 68 | $10K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 89 | $10K |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 134 | $10K |
| 73620 | <1% | 845 | $10K | |
| 73110 | <1% | 2,165 | $10K | |
| 96411 | <1% | 2,399 | $10K | |
| 84100 | <1% | 14,240 | $10K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 8,989 | $10K |
| C1769 | Guide wire | <1% | 4,965 | $9K |
| J9075 | Injection, cyclophosphamide, not otherwise specified, 5 mg | <1% | 129 | $9K |
| 73140 | <1% | 1,763 | $9K | |
| 73120 | <1% | 541 | $9K | |
| 73590 | <1% | 2,495 | $9K | |
| 96368 | <1% | 1,783 | $9K | |
| 73070 | <1% | 772 | $8K | |
| 43762 | <1% | 51 | $8K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 24 | $8K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 10,250 | $8K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 5,046 | $8K |
| G0144 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system, under physician supervision | <1% | 477 | $8K |
| 86828 | <1% | 670 | $8K | |
| 93880 | <1% | 201 | $8K | |
| 82950 | <1% | 2,630 | $8K | |
| 87116 | <1% | 1,357 | $8K | |
| 86831 | <1% | 667 | $8K | |
| 87799 | <1% | 1,002 | $8K | |
| 88342 | <1% | 3,847 | $8K | |
| 80076 | <1% | 2,070 | $7K | |
| 83970 | <1% | 666 | $7K | |
| 86762 | <1% | 2,026 | $7K | |
| 94060 | <1% | 87 | $7K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 789 | $7K |
| 86140 | <1% | 7,100 | $7K | |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 14 | $7K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 25,952 | $7K |
| 50200 | <1% | 35 | $7K | |
| 87077 | <1% | 9,786 | $7K | |
| 73562 | <1% | 905 | $6K | |
| 82607 | <1% | 2,328 | $6K | |
| 74455 | <1% | 12 | $6K | |
| 87340 | <1% | 3,963 | $6K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 385 | $6K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,025 | $6K |
| 81370 | <1% | 21 | $6K | |
| 77290 | <1% | 12 | $6K | |
| 82951 | <1% | 491 | $6K | |
| 83690 | <1% | 22,694 | $6K | |
| 86317 | <1% | 1,194 | $6K | |
| 84145 | <1% | 1,403 | $6K | |
| 86480 | <1% | 190 | $6K | |
| 83615 | <1% | 6,178 | $6K | |
| 84132 | <1% | 2,946 | $5K | |
| 81003 | <1% | 31,075 | $5K | |
| 77332 | <1% | 54 | $5K | |
| 82570 | <1% | 4,257 | $5K | |
| 86301 | <1% | 454 | $5K | |
| 93320 | <1% | 397 | $5K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,393 | $5K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 11,306 | $5K |
| 83550 | <1% | 3,519 | $5K | |
| 73090 | <1% | 2,027 | $5K | |
| 81514 | <1% | 46 | $5K | |
| 76827 | <1% | 97 | $5K | |
| 90686 | <1% | 373 | $5K | |
| 70480 | <1% | 64 | $5K | |
| 83021 | <1% | 1,114 | $5K | |
| 87186 | <1% | 8,431 | $5K | |
| G0008 | Administration of influenza virus vaccine | <1% | 550 | $5K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 14,848 | $4K |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 4,960 | $4K |
| 85730 | <1% | 13,280 | $4K | |
| 72128 | <1% | 225 | $4K | |
| 83540 | <1% | 3,646 | $4K | |
| 87486 | <1% | 358 | $4K | |
| 84156 | <1% | 3,326 | $4K | |
| 64494 | <1% | 18 | $4K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 8,856 | $4K |
| 73080 | <1% | 1,322 | $4K | |
| 82565 | <1% | 2,280 | $4K | |
| 82805 | <1% | 138 | $4K | |
| 73552 | <1% | 999 | $4K | |
| 20553 | <1% | 12 | $4K | |
| 96417 | <1% | 5,262 | $4K | |
| 31645 | <1% | 13 | $3K | |
| Q9961 | High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml | <1% | 56 | $3K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 20,634 | $3K |
| 86592 | <1% | 1,244 | $3K | |
| 51600 | <1% | 12 | $3K | |
| 89051 | <1% | 2,208 | $3K | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 2,036 | $3K |
| 95913 | <1% | 39 | $3K | |
| 87070 | <1% | 4,128 | $3K | |
| 84450 | <1% | 2,234 | $3K | |
| 72141 | <1% | 26 | $3K | |
| J3535 | Drug administered through a metered dose inhaler | <1% | 3,418 | $3K |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | <1% | 156 | $3K |
| 84550 | <1% | 3,707 | $3K | |
| 73100 | <1% | 295 | $3K | |
| 85014 | <1% | 4,368 | $3K | |
| 87581 | <1% | 374 | $3K | |
| 76000 | <1% | 1,870 | $3K | |
| 70549 | <1% | 16 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 27,072 | $3K |
| 84460 | <1% | 2,255 | $3K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 22 | $3K |
| 29130 | <1% | 44 | $3K | |
| 76857 | <1% | 54 | $3K | |
| 94727 | <1% | 102 | $3K | |
| J2704 | Injection, propofol, 10 mg | <1% | 13,198 | $2K |
| C9463 | Injection, aprepitant, 1 mg | <1% | 171 | $2K |
| 88184 | <1% | 253 | $2K | |
| 82378 | <1% | 1,451 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 14,980 | $2K |
| 76937 | <1% | 85 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 12,095 | $2K |
| 73060 | <1% | 712 | $2K | |
| 82784 | <1% | 1,645 | $2K | |
| 80164 | <1% | 407 | $2K | |
| 30300 | <1% | 17 | $2K | |
| 82952 | <1% | 491 | $2K | |
| 95912 | <1% | 25 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,092 | $2K |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 1,331 | $2K |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 1,268 | $2K |
| 88112 | <1% | 353 | $2K | |
| 71101 | <1% | 303 | $2K | |
| 82550 | <1% | 3,009 | $2K | |
| 82800 | <1% | 4,236 | $2K | |
| 85045 | <1% | 2,779 | $2K | |
| 87205 | <1% | 4,212 | $2K | |
| 97167 | <1% | 30 | $2K | |
| 73501 | <1% | 450 | $2K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 2,848 | $2K |
| 74240 | <1% | 14 | $2K | |
| 72082 | <1% | 30 | $2K | |
| 70360 | <1% | 257 | $2K | |
| Q3014 | Telehealth originating site facility fee | <1% | 131 | $2K |
| 86704 | <1% | 928 | $2K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 118 | $1K |
| 87430 | <1% | 6,008 | $1K | |
| 88304 | <1% | 3,626 | $1K | |
| 85651 | <1% | 4,312 | $1K | |
| 77280 | <1% | 12 | $1K | |
| 84153 | <1% | 736 | $1K | |
| 82746 | <1% | 965 | $1K | |
| 85007 | <1% | 969 | $1K | |
| 88313 | <1% | 310 | $1K | |
| 73000 | <1% | 231 | $1K | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 540 | $1K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 8,858 | $1K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 3,556 | $1K |
| 36416 | <1% | 2,575 | $1K | |
| 81025 | <1% | 2,728 | $1K | |
| 95909 | <1% | 14 | $1K | |
| 87147 | <1% | 678 | $1K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,460 | $1K |
| 83655 | <1% | 55 | $1K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 2,254 | $1K |
| 99152 | <1% | 1,604 | $1K | |
| 77012 | <1% | 14 | $1K | |
| G0237 | Therapeutic procedures to increase strength or endurance of respiratory muscles, face to face, one on one, each 15 minutes (includes monitoring) | <1% | 33 | $1K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 127 | $939.46 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,618 | $934.90 |
| 82330 | <1% | 2,777 | $931.99 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,597 | $930.71 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 1,196 | $889.35 |
| P9047 | Infusion, albumin (human), 25%, 50 ml | <1% | 16 | $864.51 |
| 87206 | <1% | 1,981 | $853.46 | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 2,799 | $845.65 |
| 97163 | <1% | 39 | $840.36 | |
| 83521 | <1% | 387 | $832.28 | |
| 86665 | <1% | 598 | $830.77 | |
| 82043 | <1% | 739 | $812.79 | |
| 72170 | <1% | 121 | $812.61 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 1,600 | $812.39 |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 114 | $794.40 |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,181 | $765.13 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 2,608 | $764.05 |
| 81050 | <1% | 268 | $758.15 | |
| 84403 | <1% | 412 | $728.49 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 276 | $725.69 |
| 73660 | <1% | 205 | $719.85 | |
| S0080 | Injection, pentamidine isethionate, 300 mg | <1% | 1,028 | $708.11 |
| 72192 | <1% | 24 | $688.56 | |
| 93356 | <1% | 164 | $687.16 | |
| Q9968 | Injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg | <1% | 69 | $658.44 |
| 82947 | <1% | 186 | $622.98 | |
| 94664 | <1% | 747 | $619.02 | |
| 86304 | <1% | 237 | $609.98 | |
| 76010 | <1% | 238 | $599.36 | |
| 85018 | <1% | 1,076 | $532.06 | |
| 93321 | <1% | 163 | $527.10 | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 137 | $523.14 |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 540 | $522.73 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 997 | $518.30 |
| 85652 | <1% | 1,096 | $512.77 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 141 | $504.61 |
| 86664 | <1% | 266 | $494.25 | |
| 86870 | <1% | 65 | $464.65 | |
| 84481 | <1% | 293 | $464.62 | |
| 74175 | <1% | 26 | $455.52 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,596 | $439.80 |
| 86902 | <1% | 54 | $411.12 | |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | <1% | 143 | $409.94 |
| 86038 | <1% | 268 | $398.17 | |
| M0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring | <1% | 63 | $387.29 |
| V2632 | Posterior chamber intraocular lens | <1% | 1,018 | $383.07 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,377 | $381.60 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,969 | $368.66 |
| 84165 | <1% | 324 | $362.36 | |
| 74022 | <1% | 65 | $347.08 | |
| 76098 | <1% | 12 | $333.25 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,678 | $319.88 |
| 87015 | <1% | 590 | $315.91 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 4,157 | $313.74 |
| 92567 | <1% | 12 | $302.30 | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 1,336 | $299.72 |
| 86235 | <1% | 24 | $298.14 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,381 | $296.89 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,750 | $274.30 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,907 | $233.12 |
| 87522 | Neg quan hep c or qual rna | <1% | 74 | $228.98 |
| J9250 | Methotrexate sodium, 5 mg | <1% | 744 | $222.92 |
| 84295 | <1% | 2,234 | $220.83 | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,228 | $214.70 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,468 | $212.91 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 2,517 | $199.97 |
| 90674 | <1% | 32 | $185.88 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,806 | $182.59 |
| 86156 | <1% | 49 | $180.16 | |
| 82239 | <1% | 18 | $178.46 | |
| 76001 | <1% | 12 | $171.22 | |
| 80069 | <1% | 41 | $165.25 | |
| 87517 | <1% | 25 | $155.34 | |
| 84703 | <1% | 625 | $153.08 | |
| 83516 | <1% | 55 | $151.74 | |
| 87808 | <1% | 122 | $143.30 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 528 | $138.56 |
| 87102 | <1% | 774 | $126.37 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,119 | $124.34 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 535 | $113.97 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 686 | $106.19 |
| 72158 | <1% | 12 | $100.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,505 | $97.28 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,210 | $96.41 |
| 83520 | <1% | 51 | $95.54 | |
| 86146 | <1% | 24 | $93.66 | |
| 99000 | <1% | 676 | $83.93 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,221 | $80.88 |
| 88300 | <1% | 459 | $79.05 | |
| 88302 | <1% | 45 | $78.69 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 527 | $69.92 |
| 87088 | <1% | 397 | $68.61 | |
| 82977 | <1% | 78 | $67.90 | |
| 85384 | <1% | 247 | $60.67 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,482 | $59.57 |
| 87071 | <1% | 16 | $58.20 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 1,710 | $54.94 |
| 86308 | <1% | 336 | $54.60 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 1,961 | $51.75 |
| 86696 | <1% | 12 | $47.82 | |
| 86644 | <1% | 12 | $44.77 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 573 | $40.50 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 663 | $39.65 |
| J9045 | Injection, carboplatin, 50 mg | <1% | 1,358 | $39.40 |
| 82140 | <1% | 44 | $38.52 | |
| 86225 | <1% | 25 | $36.94 | |
| 83020 | <1% | 113 | $35.93 | |
| 86695 | <1% | 12 | $35.05 | |
| 86787 | <1% | 12 | $33.16 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 628 | $30.14 |
| J9260 | Injection, methotrexate sodium, 50 mg | <1% | 198 | $28.63 |
| 82040 | <1% | 64 | $25.25 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 306 | $20.88 |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | <1% | 375 | $19.35 |
| 87184 | <1% | 117 | $18.94 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 1,434 | $18.94 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 124 | $18.43 |
| 83010 | <1% | 102 | $15.95 | |
| 99080 | <1% | 898 | $14.46 | |
| 84075 | <1% | 60 | $13.92 | |
| A9152 | Single vitamin/mineral/trace element, oral, per dose, not otherwise specified | <1% | 440 | $13.52 |
| 84155 | <1% | 60 | $13.29 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 696 | $11.95 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 572 | $11.36 |
| 87075 | <1% | 109 | $9.82 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 1,592 | $9.12 |
| 87529 | <1% | 27 | $8.29 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 109 | $7.03 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 394 | $5.95 |
| 82525 | <1% | 19 | $5.90 | |
| 84630 | <1% | 15 | $5.70 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 1,672 | $5.33 |
| 86880 | <1% | 31 | $3.11 | |
| J7699 | Noc drugs, inhalation solution administered through dme | <1% | 603 | $2.80 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 233 | $0.00 |
| J0613 | Injection, calcium gluconate (wg critical care), not therapeutically equivalent to j0612, 10 mg | 0% | 94 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 229 | $0.00 |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | 0% | 216 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 127 | $0.00 |
| 86341 | 0% | 14 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 157 | $0.00 |
| C1730 | Catheter, electrophysiology, diagnostic, other than 3d mapping (19 or fewer electrodes) | 0% | 48 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 190 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 343 | $0.00 |
| A9561 | Technetium tc-99m oxidronate, diagnostic, per study dose, up to 30 millicuries | 0% | 93 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 197 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 191 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 334 | $0.00 |
| 80177 | 0% | 49 | $0.00 | |
| 99292 | 0% | 92 | $0.00 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 181 | $0.00 |
| C1732 | Catheter, electrophysiology, diagnostic/ablation, 3d or vector mapping | 0% | 17 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 82 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 192 | $0.00 |
| 87493 | 0% | 60 | $0.00 | |
| J2280 | Injection, moxifloxacin, 100 mg | 0% | 101 | $0.00 |
| C1759 | Catheter, intracardiac echocardiography | 0% | 16 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 132 | $0.00 |
| J0611 | Injection, calcium gluconate (wg critical care), per 10 ml | 0% | 17 | $0.00 |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | 0% | 39 | $0.00 |
| C1893 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away | 0% | 16 | $0.00 |
| 82435 | 0% | 13 | $0.00 | |
| C1781 | Mesh (implantable) | 0% | 15 | $0.00 |
| 82150 | 0% | 13 | $0.00 | |
| 88331 | 0% | 16 | $0.00 | |
| C1766 | Introducer/sheath, guiding, intracardiac electrophysiological, steerable, other than peel-away | 0% | 13 | $0.00 |
| 99156 | 0% | 16 | $0.00 | |
| 0259 | 0% | 41 | $0.00 | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 0% | 64 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 500 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 481 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 580 | $0.00 |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 0% | 118 | $0.00 |
| 86618 | 0% | 13 | $0.00 | |
| J0737 | Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg | 0% | 34 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 520 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 157 | $0.00 |
| J2590 | Injection, oxytocin, up to 10 units | 0% | 14 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 4,689 | $0.00 |
| 88173 | 0% | 401 | $0.00 | |
| C1874 | Stent, coated/covered, with delivery system | 0% | 66 | $0.00 |
| 88333 | 0% | 144 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 483 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 485 | $0.00 |
| S0030 | Injection, metronidazole, 500 mg | 0% | 259 | $0.00 |
| J9000 | Injection, doxorubicin hydrochloride, 10 mg | 0% | 142 | $0.00 |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 0% | 12 | $0.00 |
| J0640 | Injection, leucovorin calcium, per 50 mg | 0% | 323 | $0.00 |
| S5010 | 5% dextrose and 0.45% normal saline, 1000 ml | 0% | 413 | $0.00 |
| Q9958 | High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml | 0% | 33 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 120 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 17 | $0.00 |
| J2720 | Injection, protamine sulfate, per 10 mg | 0% | 24 | $0.00 |
| 95874 | 0% | 12 | $0.00 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | 0% | 17 | $0.00 |
| G8989 | Self care functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 46 | $0.00 |
| J3260 | Injection, tobramycin sulfate, up to 80 mg | 0% | 17 | $0.00 |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 0% | 16 | $0.00 |
| 87328 | 0% | 61 | $0.00 | |
| C1729 | Catheter, drainage | 0% | 14 | $0.00 |
| 86334 | 0% | 15 | $0.00 | |
| A4565 | Slings | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTALENTO, RICARDO (CORPORATE CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Inova Health Care Services | Alexandria, VA | $69.02M |
| Inova Health Care Services | Leesburg, VA | $46.97M |
| Inova Health Care Services | Alexandria, VA | $39.33M |
| Inova Health Care Services | Fairfax, VA | $33.53M |
| Inova Health Care Services | Springfield, VA | $8.88M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.